Document Type
Article
Publication Date
2016
College/Unit
School of Pharmacy
Department/Program/Center
Clinical Pharmacy
Abstract
Disruption of microtubule function is the antitumor mechanism of several classes of drugs used to treat cancer today. However, the significant beneficial effect on tumor outcomes is frequently counterbalanced by neurotoxic complications. Despite an abundance of scientific data, our understanding of the biological mechanisms underlying this toxic reaction remains unclear, further hindering attempts to identify and develop effective preventive strategies. The primary goals of this review are to: (1) provide insight regarding the biology of the microtubule, (2) analyze the molecular and biochemical pathways that may be involved in the development of neurotoxicity, and (3) propose a unifying concept linking drug-induced neuropathy, microtubule dysfunction, and vitamin D.
Digital Commons Citation
Higa, Gerald M. and Sypult, Corbin, "Molecular Biology and Clinical Mitigation of Cancer Treatment-Induced Neuropathy" (2016). Faculty & Staff Scholarship. 2277.
https://researchrepository.wvu.edu/faculty_publications/2277
Source Citation
Higa, G. M., & Sypult, C. (2016). Molecular Biology and Clinical Mitigation of Cancer Treatment-Induced Neuropathy. Clinical Medicine Insights: Oncology, 10, CMO.S32810. https://doi.org/10.4137/cmo.s32810
Comments
© the authors, publisher and licensee Libertas Academica Limited. This is an open-access article distributed under the terms of the Creative Commons CC-BY-NC 3.0 License.